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Abstract 
Purpose: To formulate double-layer tablets of lornoxicam (LRX) prepared by direct compression 
method and evaluate their physical and drug release characteristics.  
Methods: The outer layer of tablets, composed of microcrystalline cellulose (MCC), starch and lactose, 
incorporated tan initial or prompt dose of the drug (4 mg) for immediate release. Hydroxypropyl 
methylcellulose (HPMC), polyvinylpyrrolidone (PVP K90) and carbomer, in varying concentrations, were 
used to prepare the tablet cores for sustained drug delivery. Weight variation, dimensions, hardness, 
tensile strength, friability and disintegration time of the tablets were evaluated. Drug release from 
double-layer tablets as well as kinetic models of drug release were determined after validating the 
method used for the quantification of the drug. The analytical method for quantification of LRX by UV 
spectroscopy was validated and verified for linearity, intra-day and inter-day precision, accuracy, 
recovery and specifity. 
Results: Tablet cores based on HPMC and HPMC:PVP K90 mixture displayed better compression and 
flow properties (good and fair to passable) than those formulated with PVP K90 and carbomer (poor). 
Satisfactory results were obtained from all the tablet formulations met compendial requirements. The 
slowest drug release rate was obtained with tablet cores based on PVP K90 (1.21 mg%.h-1). Drug 
release followed Higuchi kinetic model and the tablet cores released drug by diffusion/polymer 
relaxation or diffusion/erosion. 
Conclusion: Double-layer tablet formulation of lornoxicam based on HPMC or HPMC-PVP mixture is 
suitable for the treatment of inflammatory and painful conditions. 
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Controlled drug delivery systems are commonly 
used in therapy due to their various advantages 
over conventional dosage forms [1,2]. These 
systems meet specific therapeutic needs for 
various diseases. They delay release of drugs to 
maintain their plasma levels without a rapid onset 
of action. However, an initial dose should be 
released in the shortest time possible to relieve 
the symptoms of the disease in the case of some 
drugs including nonsteroidal antiinflammatory 
drugs (NSAIDs), antihypertensive, antihistaminic 
agents. Subsequently, drug effect should also be 
prolonged for some hours to optimize therapy [3]. 
A combination of a fast release pulse with slow 
release pattern could allow for an easier and 
more flexible optimization.  
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Double-layer and multilayer tablets have been 
developed to achieve biphasic release of drugs 
to obtain quick followed by slow drug release 
patterns [4]. A tablet core providing sustained 
drug release which is coated with a fast-
disintegrating outer layer by compression 
describes a double-layer tablet [5,6]. This kind of 
system leads to a maximum relief quickly via the 
initial burst of the coating layer. Drug release is 
followed by a sustained release phase to avoid 
repeated administration. It is also possible to 
produce this system by conventional methods 
including direct compression method which is 
more acceptable by the industry.  
 
Lornoxicam (LRX) is a NSAID from oxicam family 
which has analgesic, anti-inflammatory and 
antipyretic properties. Its mean plasma half-life 
has been reported as 3-4 h [7,8].  LRX was 
thought to display its effects by inhibition of 
cyclooxygenase (COX) isoenzymes and thus to 
inhibit prostaglandin synthesis from arachidonic 
acid. LRX is used as an alternative drug to opioid 
analgesics or as a supportive medicament in the 
treatment of postoperative pains. Its analgesic 
activity is comparable to those of opioids. Peak 
plasma concentration of LRX is reached in 2 h 
after oral administration. It is administered as 2-3 
divided doses daily.  
 
The aim of this study was to design LRX double-
layer tablets composed of a outer layer and core 
containing 4 mg initial dose and 12 mg 
maintaining dose, respectively. Thus, the 
bioavailability of LRX would be able to increase 
with double-layer tablets. Patient compliance 
could be improved when possible side effects of 
LRX could be minimized. For this purpose, 
compression characteristics and physical 






Lornoxicam (LRX) was kindly provided from Abdi 
İbrahim İlaç A.Ş. (Turkey). Carbomer (Carbopol® 
971P NF) was obtained from Lubrizol (U.S.A.). 
HPMC (Methocel® K15 Premium EP) and 
Starch® 1500 were thankfully presented by 
Colorcon (England). PVP K90 (Povidone® K90) 
was purchased from Sigma-Aldrich (Germany) 
Lactose anhydrous (DMV, The Netherlands), 
Avicel Type PH-102 (Selectchemie AG, 
Switzerland) and magnesium stearate (Prever, 
Italy) were thankfully provided from Liba 
Laboratuarları A.Ş. (Turkey). All other chemicals 
were of analytical grade.  
 
Preparation of double-layer tablets 
 
The composition of 250 mg lornoxicam double-
layer tablets are shown in Table 1. One hundred 
milligram tablet cores containing 12 mg LRX 
were compressed using a hydrolic press 
(Yeniyurt, Turkey) equipped with 7.9 mm 
diameter flat punch under 13790 kPa force. They 
were coated with an outer layer containing the 
initial dose of LRX (4 mg). Then double-layer 
tablets containing tablet cores and 150 mg outer 
layer were compressed using a 10 mm flat puch 
under 13790 kPa force. Thus, the total LRX 
content of double-layer tablets were 16 mg. 
 
Physical characterization of tablets 
 
Carr’s index (CI) (compessibility %) and Hausner 
ratio of powders composing tablet cores and 
outer layer of double-layer tablets each before 
compression were determined [9,10]. 
 
Table 1: Composition (%) of double-layer tablets 
 
Tablet    
ingredient 
Double-layer tablet (250 mg) 
Outer layer 
(% in 150 mg) 

















LRX 2.67 12 12 12 12 12 12 12 12 
HPMC - 15 20 - - - - 10 15 
PVP K90 - - - 5 10 - - 5 5 
Carbomer - - - - - 15 20 - - 
Avicel 40.67 73 68 83 78 73 68 73 68 
Starch 10 - - - - - - - - 
Lactose 46.67 - - - - - - - - 
Magnesium stearate (0.1 %) was added to both layers of the tablets 
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For this purpose, 10 g powder was poured freely 
into a 25 mL measuring cylinder and bulk volume 
(VB) was determined. Packed volume (VP) was 
obtained by tapping the powder 1250 times in a 
packed density apparatus (Erweka SVM 202, 
Germany). Thus, CI and Hausner ratio of 
samples were calculated using the following 
equations via bulk (DB) and packed (DP) 
densities: 
  
DB = 10/VB ................................................. (1) 
 
DP = 10/VP ................................................ (2) 
 
CI = [DP –DB/DP] × 100 .............................. (3) 
 
Hausner ratio = DP/DB .............................. (4) 
 
Several parameters were also determined for 
physical characterization of tablets [9,10]. Weight 
variation, friability %, hardness and in vitro 
release characteristics were determined in tablet 
cores and double-layer tablets. Swelling and 
erosion behaviours of tablet cores, and 
disintegration time of double-layer tablets were 
determined. For this purpose, 20 tablets were 
used for determination of weight variation using a 
balance (Denver Instrument). Friability % was 
determined by using 20 tablets in an Erweka TA-
220 friabilitor (Germany) for 4 min at 25 rpm. 
Hardness of tablets was tested on 10 tablets 
using a Dr. Schleuniger Pharmaton 8M hardness 
tester (Switzerland). The same hardness tester 
was used for measuring diameter and thickness 
of the same tablets. Then, tensile strength (T) 
was calculated from the fracture of tablets by 
diametral compression as described in equation 
5 [11,12], 
 
T = 2P/πDt ...................................... (5) 
 
where P is the applied load, and D and t 
represent the applied diameter and thickness of 
the tablet, respectively. 
 
Disintegration time of outer layers of double-layer 
tablets was determined on 6 tablets in 750 mL 
0.1 N HCl solution at 37 ± 0.5 oC constant 
temperature according to the method reported in 
USP 32. For this purpose, a Sotax DT2 
disintegration apparatus (Switzerland) was used.    
 
Validation of analytical method for quantifica-
tion of LRX  
 
Phosphate buffer solution at pH 7.4 (PBS pH 7.4) 
was decided to be used as the dissolution 
medium for in vitro release experiments since 
intestine is the main track for absorption of drugs 
in oral modified release dosage forms. Thus, the 
analytical method for quantification of drug by UV 
spectroscopy was obtained by dissolving LRX in 
PBS pH 7.4, validated and verified for linearity, 
intra-day and inter-day precision, accuracy, 
recovery and specificity [13]. 
 
Standard linear regression analysis was made in 
order to find out linearity of the quantification 
method. For this purpose, 2, 4, 6, 8, 10 and 12 
µg mL-1 standard LRX solutions in PBS pH 7.4 
were prepared by proper dilutions of a 1000 µg 
mL-1 stock LRX solution. Absorbance of standard 
solutions was measured using a UV 
spectrophotometer (Shimadzu UV-1700 Japan) 
at 376 nm. A calibration curve was constructed 
by plotting concentration versus absorbance. 
This study was replicated 6 times. 
 
Intra-day repeatability and inter-day intermediate 
precision, and accuracy of quantification method 
were calculated from data obtained during a 5-
day validation. Six LRX solutions in PBS pH 7.4 
(2, 4, 6, 8, 10 and 12 µg mL-1) was prepared by 
proper dilutions of the stock solution (1000 µg 
mL-1) six times on the same day. Intermediate 
precision was assessed by comparing the 
assays on different days (5 days, n = 3 at each 
concentration). Relative standard deviation 
(RSD, %) obtained gave the precision when 
accuracy was expressed as the mean relative 
error (RME, %). 
 
Recovery of the method was found by the 
standard addition technique. For this purpose, a 
known amount of standard was added to the pre-
analysed sample at 4 different levels. The 
recovery (%) was calculated using equation 6.  
 
Recovery (%) = (Ct-Cu)/Cax 100 ................ (6) 
 
where Ct is the total concentration of the analyte 
found, Cu concentration of the analyte present in 
the formulation, Ca is the concentration of the 
pure analyte added to the formulation. 
 
Specificity of the method was assayed for 
investigating whether excipients used for 
formulations interfered with quantification of LRX 
or not. Placebos of LRX formulations 
represented in Table 1 were prepared. Each of 
placebo double-layer tablets was powdered 
separately in a mortar. Powder (0.5 g) was 
weighed into a 25 mL volumetric flask to which 
10 mL of PBS pH 7.4 was added and the mixture 
was kept in an ultrasonic bath for 15 min. The 
mixture was filtered through a S & S5893 blue 
ribbon filter paper (Schleicher und Schuell, 
Germany) after being diluted to 25 mL with 
additional medium. Supernatant (1 mL) was 
withdrawn and diluted properly final solution was 
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assayed by UV spectroscopy. Each study was 
replicated 6 times. 
 
In vitro release study 
 
Drug release from tablet cores and double-layer 
tablets was studied according to the USP 32 
Method II (paddle) at 37 ± 0.5 oC in 900 mL PBS 
pH 7.4 at 50 rpm rotation speed. Samples 9 mL 
were taken from dissolution medium at 
predetermined time intervals. They were diluted 
to 10 mL and filtered through ablue ribbon filter 
paper. They were assayed by UV spectroscopy 
at 376 nm. 
 
Drug release profiles from tablet cores and 
double-layer tablets was evaluated using 
different kinetic models. Eqs. 7 - 9 describe zero-
order, first-order and Higuchi root-square models 
as follows [14,15], 
 
Qt = Q0+ k0t ......................................(7) 
 
where Qt and Q0 are amount of drug released at 
time t and in the dissolution medium at t = 0 
(usually, Q0 = 0), respectively, and k0 is the zero-
order release constant.  
 
Qt = Q∞ (1 - e -k1t) ............................... (8) 
 
where Q∞ represents the total amount of drug in 
the matrix and k1 is the first-order kinetic 
constant. 
 
Qt = kHt1/2 .......................................... (9) 
 
where kH is the Higuchi rate constant.  
 
Drug release profiles were also evaluated using 
Korsmeyer-Peppas equation (exponential 
equation) (Eq. 10) since these models could fail 
to explain drug release mechanism in case of 
swelling along with gradual erosion of the matrix 
due to hydration [16], 
 
Log [Qt/Q∞] = log k + nlogt ............. (10) 
 
Swelling and erosion behaviours of tablet cores 
were investigated after immersion of the tablets 
in the dissolution medium PBS pH 7.4. Thus, 
relationship between drug release and polymer 
hydration could be clarified [17]. Tablets were 
weighed (W0) and placed in beakers each 
containing a mesh underneath the tablets in PBS 
pH 7.4. Beakers were closed and placed a 
waterbath (Daihan Scientific, Korea) kept at 37 ± 
0.5 oC constant temperature during the study. 
After 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours, 
beakers were removed from the water bath. 
Tablets with meshs were withdrawn from the 
medium and blotted to remove excess water and 
the tablets weighed (W1). Wet samples were kept 
in a climatic test cabinet (Nüve TK 120, Turkey) 
at 80 °C and 10 % relative humidity for 24 h time 
period. They were then allowed cooling in a 
desiccator and weighed until constant weights 
were achieved for each of them. Thus, final dry 
weight (W2) of each sample was obtained. The 
experiment was performed in triplicate for each 
time point. Increase in weight due to absorbed 
liquid or medium uptake was estimated at each 
time point from Eq. 11 when remained % of 
tablets at the 24th hour was calculated using Eqs 
12 and 13. 
 
Weight change (%) = [(W1 – W2)/W0] x 100…….. (11) 
 
Remained % = 100 – ES ........................ (12) 
 




In vitro drug release data were evaluated using 
GraphPad Prism 5 software and one-way 
ANOVA to determine differences for release 
profiles, swelling and erosion data of all 




Physical properties of LRX double-layer 
tablets 
 
CI in the ranges of 12-16 and 18-21 displays 
respectively good and fair to passable flowability. 
Hausner ratio of a powder below 1.25 indicates 
good flowability, while above 1.6 predicts 
cohesion of particles [10]. Thus, CI values and 
Hausner ratios give information on flowability and 
compressibility of powder mixtures of outer layer 
and tablet cores (Table 2). The result of physical 
characteristics of tablet cores and double-layer 
tablets provided good weight uniformity indicating 
low standard deviations up to ± 1.2 (relative 
standard deviations lower than 0.5 %) as can be 
seen in Table 2. Hardness of tablet cores and 
double-layer tablets ranges from 106-200 N and 
78-147 N, respectively. The lowest hardness 
values led to the lowest tensile strength. Tablet 
cores passed the friability test with values lower 
than 0.5 % while the highest friability was 
obtained as 1.0 %, which is an acceptable value 
according to the compendial sources in the case 
of double-layer tablets. Outer layers of all double-
layer tablets disintegrated within 45 ± 0.016 s. 
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Table 2: CI values and hausner ratios of powder mixtures and physical characterization of LRX double-layer 
tablets 
 









strength          
(T) (Mpa) 







 core HPMC-1 20.09 (Fair to passable) 1.25 102 ± 0.2 106 ± 3.92 5.22 ± 0.10 
core HPMC-2 16.75 (Good) 1.20 101 ± 0.2 106 ± 2.94 5.13 ± 0.07 
core PVP-1 33.34 (Poor) 1.50 102 ± 0.2 111 ± 3.91 5.53 ± 0.10 
core PVP-2 31.58 (Poor) 1.46 103 ± 0.2 111 ± 3.92 5.31 ± 0.11 
core Ca-1 34.99 (Poor) 1.54 102 ± 0.2 200 ± 8.88 9.79 ± 0.43 
core Ca-2 34.88 (Poor) 1.54 102 ± 0.2 178 ± 5.88 8.84 ± 0.29 
core HPMC-PVP-1 21.28 (Fair to passable) 1.27 101 ± 0.2 123 ± 2.94 5.99 ± 0.14 












HPMC-1 - - 249 ± 1.2 78 ± 3.91 2.01 ± 0.10 
HPMC-2 - - 248 ± 0.5 93 ± 3.92 2.41 ± 0.10 
PVP-1 - - 249 ± 0.6 86 ± 5.89 2.22 ± 0.12 
PVP-2 - - 250 ± 0.9 90 ± 4.91 2.33 ± 0.10 
Ca-1 - - 249 ± 0.6 147 ± 7.85 3.82 ± 0.20 
Ca-2 - - 248 ± 0.5 140 ± 4.91 3.61 ± 0.13 
HPMC-PVP-1 - - 248 ± 0.5 99 ± 5.88 2.55 ± 0.15 




Absorption spectra of LRX showed λmax at 376 
nm. The representative linear equation was A = 
aC + b, where C is the concentration, A = the 
absorbance, a = the slope, and b is the intercept. 
In the current method, regression equations were 
A = 22.894C – 0.078 with r = 0.9999 in PBS pH 
7.4.  
 
Intra-day and inter-day R.S.D. values obtained 
by the proposed method were found to be 
between 0.40-1.90 %. Accuracy of the method 
was also expressed here as R.M.E. lower than 2 
%, between 0.08 % and 1.67 %. Recovery of 
LRX was found between 99.77 % ± 0.002 and 
100.45 % ± 0.002 by standard addition method. 
 
Quantification method was specific for LRX 
detection. Constituents in formulations did not 
display absorbance at 376 nm which was the 
maximum wavelength for LRX in PBS pH 7.4. 
 
In vitro drug release  
 
Fast-disintegrating outer layer of all double-layer 
tablets released their LRX content within 45 min 
(p > 0.05). This is similar to the release profile 
obtained in the conventional tablet containing the 
individual dose of the drug (Figure 2a,b). 
Subsequently, tablets displayed sustained drug 
delivery since their tablet cores released drug in 
a longer time period. Statistically significant 
differences were detected among LRX release 
profiles obtained from tablet cores of all 
formulations (p < 0.05). The slowest LRX release 
rate (1.21 mg%.h-1) was obtained with double-
layer tablets based on PVP K90 in the tablet core 
(formulations PVP-1 and PVP-2) followed by 
formulations HPMC-2 (2.31 mg%.h-1), HPMC-
PVP-2 (2.38 mg%.h-1), HPMC-1 (2.80 mg%.h-1), 
HPMC-PVP-1 (2.89 mg%.h-1), Ca-2 (3.21 
mg%.h-1) and Ca-1(3.26 mg%.h-1). Double-layer 
tablets released LRX according to Higuchi kinetic 
model (Table 3). 
 
Swelling and erosion behaviour of tablet 
cores  
 
As can be seen in Figure 1, the highest swelling 
rate was observed with carbomer based tablet 
cores (Ca-2 and Ca-1) followed by formulations 
HPMC-PVP-2, HPMC-PVP-1, HPMC-1, HPMC-
2, PVP-1 and PVP-2 (p < 0.05). 52.75 and 52.01 
% of carbomer based tablet cores were remained 
at the end of 24 h indicating diffusion governed 






















Figure 1: Change in weight of tablet cores for 24 h; ◊ 
= core HPMC-1, □ = core HPMC-2, x = core PVP-1, - 
= core PVP-2, ▲ = core Ca-1, ■ = core Ca-2, Δ = core 
HPMC-PVP-1, ● = core HPMC-PVP-2. 
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Figure 2a,b: Release profiles of LRX from tablet cores and their double-layer tablets. Figure 2a; −◊− = core 
HPMC-1, −□− = core HPMC-2, --◊-- = core PVP-1, --□-- = core PVP-2, −○− = core Ca-1, −Δ− = core Ca-2, --○-- = 
core HPMC-PVP-1, --Δ-- =  core HPMC-PVP-2, Figure 2b; −♦− = HPMC-1, −■− = HPMC-2, --♦-- = PVP-1, --■-- = 
PVP-2, −●− = Ca-1, −▲− = Ca-2, --●-- = HPMC-PVP-1, --▲-- = HPMC-PVP-2. 
 















(g/h) x 103 
r K0  r K1  R D  r n   
Tablet cores 
core HPMC-1 0.936 3.14  0.763 0.09  0.997 17.84  0.997 0.59 Non-Fickian 3.425 
core HPMC-2 0.989 3.03  0.796 0.14  0.986 16.14  0.998 0.83 Non-Fickian 3.057 
core PVP-1 0.857 1.90  0.698 0.09  0.968 11.45  0.986 0.61 Non-Fickian 2.065 
core PVP-2 0.859 1.48  0.718 0.08  0.968 8.91  0.989 0.57 Non-Fickian 1.624 
core Ca-1 0.895 3.92  0.691 0.17  0.970 22.70  0.976 1.20 Supercase II 3.631 
core Ca-2 0.904 3.61  0.695 0.18  0.970 20.62  0.980 1.27 Supercase II 3.314 
core  
HPMC-PVP-1 0.904 2.62  0.752 0.09  0.986 15.21  0.992 0.60 Non-Fickian 2.790 
core  
HPMC-PVP-2 0.996 3.99  0.842 0.13  0.972 20.79  0.983 0.77 Non-Fickian 4.014 
Double-layer tablets 
HPMC-1 0.996 2.80  0.951 0.05  0.976 14.65  0.947 n/a n/a 3.905 
HPMC-2 0.985 2.31  0.931 0.05  0.991 12.42  0.957 n/a n/a 3.363 
PVP-1 0.950 1.21  0.903 0.03  0.999 6.77  0.975 n/a n/a 2.280 
PVP-2 0.934 1.21  0.883 0.03  0.996 6.90  0.980 n/a n/a 2.220 
Ca-1 0.944 3.26  0.849 0.06  0.994 18.33  0.974 n/a n/a 4.085 
Ca-2 0.966 3.21  0.891 0.06  0.987 17.51  0.952 n/a n/a 4.020 
HPMC-PVP-1 0.984 2.89  0.922 0.05  0.991 15.56  0.969 n/a n/a 4.167 
HPMC-PVP-2 0.976 2.38  0.914 0.05  0.995 12.93  0.967 n/a n/a 3.405 
r, correlation coefficient; K0, zero order release constant (mg%/h); K1, first order release constant (h-1); D, 
diffusion coefficient (mg%/h1/2); n, release exponent; n/a, not applicable 
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The physical characteristics of the double-layer 
tablet formulations conformed to compendial 
requirements. Parameters describing physical 
properties of tablets demonstrated mechanical 
strengths of formulations. In spite of poor 
compression characteristics of core tablets 
based on PVP K90 and carbomer, the double-
layer tablets displayed good inter-layer adhesion 
as expected. 
 
The outer layer of double-layer tablets displayed 
a good flow and compression characteristics 
when characteristics of tablet cores were variable 
depending on their polymer content (Table 2). 
Among the other polymers, carbomer caused the 
weakest compression quality for tablet cores 
(core Ca-1 and core Ca-2) indicating cohesion of 
powder particles and possible compression 
problems in a case of large scale production. 
PVP K90 followed carbomer with poor flow and 
compression quality of tablet cores (Formulations 
core PVP-1 and core PVP-2). Increase in 
concentrations of carbomer and PVP K90 did not 
affect the powder characteristics. However, 
HPMC and HPMC:PVP K90 mixture resulted in 
good or fair to passable flowability and 
compressibility all ratios in the formulations.  
 
Increase in avicel concentration increased drug 
diffusion rate from tablet cores (Table 3). 
Carbomer based tablet cores (core Ca-1 and 
core Ca-2) displayed Supercase II transport, 
which is typical for cylindrical matrix tablets 
indicating coupled diffusion/polymer relaxation, 
when the other formulations released drug in the 
non-Fickian kinetic correspond to coupled 
diffusion/erosion. When a matrix tablet containing 
hydrophilic polymers for sustaining drug release 
gets in contact with an aqueous medium, the 
medium passes into the matrix tablet structure 
and polymer at surface turns into a gel at first 
[10,14]. In the case of carbomer based tablet 
cores, system swelled by continuous medium 
transfer into tablets. Diffusion was governed by 
Fick’s law and supercase II transport which 
reflects the influence of polymer relaxation on 
molecules’ movement in the matrix, here [18,19]. 
However, tablet erosion follows polymer 
relaxation via the lost of the outer gel layer in the 
case of non-Fickian drug release. In other words, 
transfer of the dissolution media into the system 
continues and outer gel layer starts to regenerate 
followed by tablet erosion.  
 
Swelling and erosion experiments on tablet cores 
also helped us describing drug release 
characteristics of tablets. Polymer relaxation and 
matrix swelling in carbomer based tablet cores 
(core Ca-1 and core Ca-2) are clearly reflected 
by Figures 2 and 3. Swelling of those tablet cores 
reached to a maximum at the 8th h and they 
could maintained about 52 % of their size at the 
24th h indicating Supercase II transport as the 
dominant drug release mechanism. However, 
tablet erosion was detected with the tablet cores 
of other formulations displaying remaining 




Double-layer tablets particle for tablet cores 
based on HPMC and HPMC-PVP mixture 
displayed better flow and compression properties 
while the slowest drug release profiles were 
obtained with PVP K90 based tablet cores. 
Although, PVP K90 and carbomer based tablet 
cores displayed poor flow and compression 
properties indicating possible problems for large-
scale production, double-layer tablets of all 
formulations showed desired physical 
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characteristics. Outer layer and tablet cores of all 
formulations displayed adequate adhesive 
properties. It was concluded that double-layer 
tablets designed in this study could be used in 
the treatment of inflammatory conditions 
reducing frequency of dosing and providing 
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